Although detection of autoantibodies in the peripheral blood from patients with immune-
Introduction
Autoantibodies directed against normal host antigens are a common feature of many autoimmune diseases. Some of the markers are pathogenic, whereas others they may be merely an epiphenomenon due to tissue damage and serve as markers for organ involvement or outcomes. 1 Pathogenic autoantibodies may act directly on target organs by immunecomplex deposition, complement activation or by binding distinct soluble or membrane proteins blocking or activating their biological activity. 2 Anti-endothelial cell antibodies (AECA) are a heterogeneous group of antibodies detected in autoimmune vasculitis, vasculopathies, atherosclerosis and other diseases caused by vessel-wall damage. 3 AECA induce an endothelial perturbation in vitro, increasing adhesion molecule expression and secretion of pro-inflammatory cytokines and chemokines. Some evidence suggests that AECA favour ischemic events by inducing apoptosis. [4] [5] [6] [7] The pathogenetic role of AECA in ischemia receives support from their frequent association with disease activity in several autoimmune vasculitis and vasculopathies including Behçet's disease (BD), systemic lupus erythematosus (SLE) and systemic sclerosis (SS). 3, 8, 9 Until recently, few published data were available on the endothelial cell autoantigens recognized by AECA. 10 Identifying endothelial autoantigens involved in the immune-mediated processes during endothelial dysfunctions could help to explain how chronic inflammation of the vascular wall initiates and progresses.
Screening a cDNA expression library is a powerful technique that identifies previously uncharacterized antigens from patients' sera containing antibodies.
In this study, designed to identify new antigenic targets of AECA, we screened a human microvascular endothelial cell (HMVEC) cDNA expression library with sera from patients with BD, a systemic form of primary vasculitis and identified a strongly reactive clone encoding Ral binding protein1 (RLIP76/RALBP1). RLIP76 is a Ral effector, GTPaseactivating protein 11 expressed in several malignant cell lines and, in smaller amounts, in non-
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We studied thirty-seven unselected out-patients with BD (10 women, 27 men; mean age 42.2 years, range 27-58 years; mean disease duration 7.9 years, range 0-24 years), 40 with an elevated erythrocyte sedimentation rate and positive C-reactive protein were assumed to have active disease. According to these criteria, 44.4 % of patients had active disease. The frequency of the HLAB51 allele was 68.7%. SLE was diagnosed in accordance with the American College of Rheumatology revised criteria. 25 Glucocorticoids were used in 74% of patients with SLE, hydroxychloroquine in 48.1%, immunosuppressive drugs (azathioprine, cyclophosphamide, cyclosporine A, methotrexate, mycophenolate mofetil) in 37%, and 11.1%
were not treated. SS was diagnosed in accordance with the criteria of the American Rheumatism Association. 26 Of the 65 patients with SS 15 were receiving low doses of glucocorticoids (<10 mg prednisone daily) and 9 patients were also undergoing immunosuppressive therapy (cyclosporine A or cyclophosphamide). As controls, we also enrolled 43 patients with infectious mononucleosis and 46 healthy subjects (27 women, 19
men; mean age 45 years, range 34-53 years).
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From We also enrolled 66 consecutive patients with carotid atherosclerosis undergoing carotid endarterectomy at the Department of Surgical Sciences of University of Rome, "Sapienza". The indications for surgery, based upon the recommendations published by the Asymptomatic Carotid Atherosclerosis Study and the North American Symptomatic Carotid Endarterectomy Trial were clinically asymptomatic, severe or pre-occlusive carotid-artery stenosis equal to or more than 70%, clinically asymptomatic stenosis with ipsilateral signs of cerebral ischemia on computed tomographic scan and clinically symptomatic stenosis.
27, 28 To correct cardiovascular risk factors, all patients received 150 mg of aspirin for 4 weeks before endarterectomy. Exclusion criteria were recent infection (< 1 month), autoimmune disease, malignancy and inflammatory diseases. We also excluded patients receiving statins. Venous peripheral blood was drawn from patients before endarterectomy and from 25 sex-and agematched healthy subjects with no ultrasonographically evident carotid atherosclerotic disease recruited as controls.
Informed consent was obtained from each patient and the Istituto Superiore di Sanita
Institutional Review Board approved the study.
Immunoscreening of the cDNA expression library
A commercially available HMVEC cDNA library (Stratagene, Cambridge, UK) was screened with the serum from 2 of the 37 patients with BD, essentially as previously described. 29 The two patients'sera were selected on the basis of their AECA positive immune reaction and disease activity. Positive plaques were re-screened with the same pool of sera to obtain the clonality and phages were recovered as pBluescript by single-stranded rescue using the helper phage (Stratagene) according to the manufacturer's instructions and used to transform SolR XL1 cells. 
Identification, amplification and cloning in expression vector of the cDNA subunits
The nucleotide sequence of the cloned cDNA insertions was sequenced with automated sequencer ABI Prism 310 collection (Applied Biosystems, Foster City, CA, USA) and the sequence compared with the GenBank sequence database using the Blast program revealed 100% identity with RLIP76 (NM 006788). The cDNA insertion was amplified by PCR to obtain the N-and C-terminal regions using as primers the oligonucleotides with restriction sites. For the N-terminal region we used: forward (BamHI restriction site underlined) 5′ GCATGGATCCATGACTGAGTGCTTCCTG 3′, reverse (Hind III restriction site underlined) 5′ GCATAAGCTTAGTTCCTTTGCAATGACATG 3′; for the C-terminal subunit we used: forward (BamHI restriction site underlined) 5′ GCATGGATCCCCAGAATGTAACTATCTTCTG 3′, reverse (HindIII restriction site underlined) 5′ GCATAAGCTTTCAGATGGACGTCTCCTT 3′. The amplified fragments were run in 2% agarose gel, purified by Qiaex kit following the manufacturer's instruction (Qiagen GmbH, Hilden, Germany) and after digestion with the restriction enzymes (Promega Corporation, Madison, Wisconsin, USA) cloned in pQE (Qiagen) expression vector.
Expression and purification of the recombinant antigens
The fusion proteins were expressed in Escherichia coli SG130009 cells, purified by affinity of NI-NTA resin for the six-histidine tail and eluted under denaturing conditions according to the manufacturer's instruction (Qiagen) using a protease inhibitor cocktail (Sigma-Aldrich, St Louis, MO, USA).
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SDS-PAGE and immunoblotting
After 10% SDS-PAGE under reducing conditions, immunoblotting was performed as previously described. 30 In brief, the antigen was loaded at concentrations of 3 μg/lane and was revealed by human sera diluted 1:100 and by a monoclonal antibody to six-histidine tail (Qiagen). Peroxidase-conjugated goat anti-human IgG and anti-mouse IgG sera (Biorad, Richmond, CA, USA) were used as second antibodies. Strips were developed with 3-3'
diaminobenzidine (Sigma-Aldrich).
ELISA
ELISA was developed essentially as previously described. 31 In brief, polystyrene plates (Maxisorp, Nunc, Rochester, NY) were coated with the antigen (0.1 μg/well) in 0.05 M NaHCO 3 buffer, pH 9.5, and incubated overnight at 4°C. Plates were blocked with 100 μl/well of PBS with 0.05% Tween20 (PBS-Tween) containing 3% milk, for 1 hour at 37 °C. Optimal serum dilution was established in preliminary experiments (1:10-1:500). For the RLIP76 Cterminal subunit serum reactivity peaked at a dilution of 1:100 and remained unchanged at higher concentrations whereas for the RLIP76 N-terminal subunit it remained under detectable values at each serum dilution tested (data not shown). After blocking with 3% milk, plates were therefore incubated with human sera diluted 1:100 in PBS-Tween and 1% milk. Peroxidase conjugated goat anti-human IgG (Biorad) diluted 1:3000 in PBS-Tween containing 1% milk was incubated 1 hour at room temperature. O-phenylenediamine dihydrochloride (Sigma-Aldrich) was used as substrate and the optical density (OD) was measured at 490 nm. Means + 2 standard deviations of the OD reading of the healthy controls were considered as the cut-off level for positive reactions. All assays were performed in
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From quadruplicate. Data were presented as the mean OD corrected for background (wells without coated antigen). The results of unknown samples on the plate were accepted if internal controls (two serum samples, one positive and one negative) had an absorbance reading within mean ± 10% of previous readings. To inhibit specific IgG, the sera from two patients with BD were incubated overnight at room temperature with 10 μg/ml of the same antigen used to coat ELISA plates according to the method reported by Huang and colleagues. 32 As negative controls for the inhibition analysis, the sera were pre-incubated with 10 μg/ml of an unrelated recombinant antigen or 40 μg/ml of bovine serum albumin.
Cultures of human umbilical-vein endothelial cells (HUVEC) at the third to fourth passage were used to detect AECA (IgG), using a cell-surface ELISA on living cells, as previously reported.
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Antibodies specific to RLIP76
Antibodies from patients' sera were purified as previously described. 29 In brief, antigen (50 μg) was spotted onto a nitrocellulose filter and incubated with the sera from patients with BD used for the immunoscreening. The bound antibodies were eluted with glycine 100 mM, pH 12 As a control we used the same concentration of human IgG in the medium. To rule out endotoxin contamination the same experiments were run in the presence of polymyxin B (10 μg/ml) (Sigma-Aldrich). In some experiments, cells were also pre-incubated for 2 hours with 30 µM pan-caspase inhibitor zVAD (Alexis, San Diego, CA, USA) or for 24 hours with 30 µM alpha-tocopherol (α-TCPH, Sigma-Aldrich).
Cellular localization of RLIP76
An indirect immunofluorescence assay was developed on endothelial cells, as previously described. 34 Cells were permeabilized with acetone/methanol 1/1 (vol/vol) for 10 min at 4°C, soaked in balanced salt solution (Sigma) for 30 min at 25°C and then were incubated for 30 min at 25°C in the blocking buffer (2% BSA in PBS, containing 5% glycerol and 0.2% 
RLIP76 immunoprecipitation
Cell-free lysates from EAhy926 were immunoprecipitated with mouse polyclonal anti-RLIP76 C-ter antibodies. In brief, cells were lysed in lysis buffer (20 mM HEPES, pH 7.2, 1% Nonidet P-40, 10% glycerol, 50 mM NaF, including protease inhibitors). To preclear nonspecific binding, cell free lysates were mixed with protein A-acrylic beads (Bio-Rad) and stirred in a rotary shaker for 1 hour at 4°C. After centrifugation (500 x g for 1 min), the supernatant was immunoprecipitated with mouse polyclonal anti-RLIP76 C-ter antibodies (3 µg) plus protein A-acrylic beads. The immunoprecipitates were subjected to 7.5% SDS-PAGE and immunoblotting with human anti-RLIP76 antibodies. Immunoreactivity was assessed by the chemiluminescence reaction using the enhanced chemoluminescence (ECL)
Western blotting system (Amersham).
Immunohistochemistry
The superior thyroid artery, obtained from a patient after thyroidectomy, was immediately frozen. Cryostat sections of the artery were incubated with mouse anti-RLIP76 serum and with a biotinylated anti-mouse antibody and peroxidase-labeled streptavidin. Specimens were reincubated with 3,3′-diaminobenzidine tetrahydrochloride (DAB, Sigma-Aldrich) and nuclei were counterstained with Mayer's haematoxylin. Controls included isotype-matched IgG and elimination of the primary antibody step.
4-Hydroxynonenal quantification
To evaluate the formation of 4-HNE adducts with histidine cells fixed with 4%
paraformaldehyde and permeabilized with 0.5% Triton X-100 (Sigma-Aldrich) were stained with specific monoclonal antibody against 4-HNE (10 µg/ml, R&D Systems, Inc.
Minneapolis, USA) for 1hour at 4°C. After washing cells were incubated with an anti-mouse antiserum conjugated with Alexa-488 (Molecular Probes, Eugene, OR, USA). After 30 min at 37° C, cells were washed twice and then analyzed on a cytometer. For fluorescence microscopy observations, cells were also counterstained with Hoechst before analyses by a Nikon Microphot equipped with intensified video microscopy (IVM) by a CCD camera (Carl Zeiss, Germany).
Staining for intracellular GSH
Intracellular GSH was detected by monochlorobimane (Molecular Probes) staining as previously described. 35 For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From
Activation of caspase-3
The activation state of caspase-3 was evaluated with the CaspGLOW fluorescein active caspase staining Kit (MBL, Woburn, MA, USA). Control and treated cells were incubated with FITC-conjugated caspase-3 inhibitor (DEVD-FMK) for 1 hour at 37°C, following the manufacturer's instructions. Samples were thereafter washed three times and immediately analyzed on a cytometer equipped with an FL-1 channel.
Activation of JNK
To evaluate the activation state of JNK by flow cytometry, we used a rabbit anti-JNK polyclonal antibody (BD/Pharmingen Oxford, UK) able to recognize human JNK1 phosphorylated at T183 and Y185. Cells were fixed with paraformaldehyde (4% in PBS), permeabilized with Triton X-100 (0.05% in PBS) and then stained with anti-JNK (pT183/pY185) followed by addition of FITC-conjugated anti-rabbit for 45 minutes at 4°C.
After washings, cells were resuspended in PBS and analyzed on a cytometer.
Statistical analysis
For the analysis of the associations between the clinical characteristics of patients and anti-RLIP76 antibodies chi-square test was used to evaluate differences between percentages and Unless otherwise indicated, P values of less than 0.01 were considered significant.
Results
Identification of RLIP76 by immunoscreening of the HMVEC expression library and its characterization
To identify genes encoding putative endothelial antigens we immunoscreened a HMVEC expression library with IgG from the serum of two patients with BD. Besides clones with cDNA insertion of Sip1, a known BD autoantigen; 29 we identified, other strongly reactive clones with a 1968 base-pair open reading frame and a predicted amino acid sequence 655 residues long that had 100% identity with the glutathione conjugate transporter RLIP76. To identify the immunoreactive region of RLIP76 we cloned and expressed two distinct overlapping subunits corresponding to the N-and the C-terminal fragments ( Figure 1A ).
These fragments showed the expected molecular sizes of 41.1 kDa for the C-terminal region and 39.2 kDa for the N-terminal region by 10% SDS-PAGE. In immunoblotting analysis the patients' serum IgG used for immunoscreening the library recognized only the C-terminal fragment of RLIP76 (RLIP76 C-ter Figure 1B ).
Serum IgG immunoreactivity to RLIP76
We analyzed serum IgG immmunoreactivity to the N-and C-terminal regions of RLIP76.
When we investigated the prevalence of serum anti-RLIP76 C-ter antibodies in patients with diseases characterized by endothelial dysfunction and controls, ELISA detected IgG specific to RLIP76 C-ter in sera from all the groups of patients studied (11/37 (30%) patients with BD, 11/65 (17%) patients with SS and 10/40 (25%) patients with SLE) but in no sera from controls (patients with mononucleosis or age-and sex-matched healthy subjects) ( Figure 2A ).
ELISA also detected serum anti-RLIP76 C-ter antibodies in 27 of the 66 patients with carotid atherosclerosis (41%) but in no age-and sex-matched healthy subjects ( Figure 2B ). Preabsorption with RLIP76 C-ter itself of the sera from two patients with BD completely inhibited the antibody immunoreactivity thus confirming the specificity of ELISA (data not shown). No tested patients' or controls' sera reacted with RLIP76 N-ter (OD 490 < 0.05). To assess the association of the clinical features in each disease with anti-RLIP76 C-ter antibody reactivity we then subgrouped the patients according to the presence of serum anti-RLIP76 Cter antibodies. For BD we considered ocular, genital, skin or vascular involvement (Table 1); for SLE, SLEDAI, skin or kidney involvement, neuropsychiatric manifestations and serological markers (triglycerides, cholesterol, HDL, LDL) ( Table 2) ; for SS, lung fibrosis and skin score (Table 3) ; and for carotid atherosclerosis, diabetes, hypertension, cardiovascular diseases in relatives and hypercholesterolemia (Table 4) . Although no significant difference was found between the presence of serum anti-RLIP76 C-ter antibodies and clinical variables, in the SS group, sera from patients with lung fibrosis more frequently contained RLIP76 C-ter antibodies than sera from patients without (6/11, 54% vs 18/54, 33%). Considering as indicators of disease activity SLEDAI for patients with SLE, skin score and lung fibrosis for patients with SS, and the criteria defined in Material and Methods for patients with BD, we found no significant association between the presence of serum anti-RLIP76 antibodies and disease activity. No association was found between the presence of serum anti-RLIP76 antibodies and serum AECA or therapeutic regimen in the various subgroups (data not shown). Overall these data suggest that anti-RLIP76 antibodies are a new immunological marker shared by patients with various immune-mediated endothelial diseases.
Localization of RLIP76 in EAhy926 cells under physiological conditions and after oxidative stress
We analyzed RLIP76 expression in EAhy926 endothelial cells and in vascular tissue.
Immunoprecipitation analysis showed that RLIP76 antibodies can immunoprecipitate the protein from EAhy92 endothelial cells in vitro ( Figure 3A ). Immunohistochemistry provided evidence that this protein is expressed on vascular endothelium in vivo ( Figure 3B ). To find out whether oxidative stress induces a redistribution of RLIP76 from the intracellular compartment into the membrane surface of endothelial cells, and to identify the extracellular region we analyzed qualitatively (by fluorescence microscopy) and quantitatively (by flow cytometry) RLIP76 C-ter in EAhy926 cells under physiological conditions and under mild oxidative stress. 23, 36 Immunofluorescence analysis with human purified antibodies specific to RLIP76 C-ter disclosed a redistribution of RLIP76 C-ter on the surface membrane of oxidative-stressed cells ( Figure 3C ). Accordingly, semi-quantitative analysis of surface expression clearly showed that under physiological conditions, RLIP76 C-ter was weakly expressed in the membrane. Under mild oxidative stress, membrane expression rapidly increased at 30 min, peaked at 6 hours and diminished at 24 hours ( Figures 3D,E) .
Effects of anti-RLIP76C-ter antibodies on intracellular 4-HNE and GSH levels in
EAhy926 endothelial cells
To find out more about the role of RLIP76 in the cell response to oxidative stress we studied the effects of anti-RLIP76 C-ter antibodies on EAhy926 endothelial cells under physiological conditions and after mild oxidative stress.
First, we analyzed the formation of 4-HNE adducts with histidine ( Figures 4A-C) . As expected, when endothelial cells were exposed to H 2 O 2 , 4-HNE formation increased ( Figures 4A,C) . When cells were allowed to recover for 24 hours in fresh culture medium, 4-HNE levels returned to baseline. Adding anti-RLIP76 C-ter antibodies to the medium completely prevented endothelial cell recovery ( Figures 4B,C) . A time-course analysis in H 2 O 2 -treated cells clearly confirmed that the time-dependent recovery of 4-HNE to baseline levels was abolished by adding anti-RLIP76 C-ter antibodies to the medium ( Figure 4D ). 4-HNE levels were significantly higher in cells incubated for 6 h and 24 h with anti-RLIP76 C-ter antibodies than in cells cultivated without. In untreated endothelial cells, anti-RLIP76 C-ter antibodies also induced per se a time-dependent increase in 4-HNE ( Figure 4D ).
Because intracellular 4-HNE detoxification involves the most abundant cellular thiolcontaining peptide, GSH, we analyzed the time courses of endothelial intracellular GSH content. 37 At 30 min after cells had been exposed to H 2 O 2 , intracellular levels of GSH decreased significantly and at 6 h and 24 h recovered to baseline levels. The time-dependent recovery of GSH levels was abolished by adding anti-RLIP76 C-ter antibodies to the medium.
In untreated cells incubated for 30 min, 6 h and 24 h with anti-RLIP76 C-ter antibodies GSH levels significantly decreased ( Figure 4E ). Linear regression analysis showed a strong negative correlation between intracellular 4-HNE and GSH (r = -0.94, P < 10 -4 ). Control purified total IgG from healthy subjects left 4-HNE and GSH levels appreciably unchanged (data not shown). Collectively, these data suggest that anti-RLIP76 C-ter antibodies not only lower physiological cellular defenses against oxidative stress, but also directly per se increase the formation of oxidative by-products.
Effects of anti-RLIP76C-ter on induction of cellular apoptosis
The well-known relationship among apoptosis, 4-HNE and GSH prompted us next to analyze the possible role of anti-RLIP76 C-ter antibodies as an apoptotic inducer in endothelial cells. 38 Anti-RLIP76 C-ter antibodies induced apoptosis in a significant percentage of H 2 O 2 -treated D) . We also found that apoptosis induced by anti-RLIP76 C-ter antibodies was caspase-dependent as evidenced by detection of caspase-3 enzymatic activity ( Figures 6A,B) . The pan-caspase inhibitor zVAD significantly prevented anti-RLIP76 C-ter antibody-induced caspase-3 activation ( Figure 6C) and apoptosis (data not shown).
To find out whether anti-RLIP76 -ter antibodies activate the typical oxidative signaling pathway, we investigated JNK phosphorylation. Treatment with anti-RLIP76 C-ter antibodies, either alone or in combination with H 2 O 2 , led to the phosphorylation of JNK in a large percentage of cells. JNK activation started after 30 minutes, peaked after 6 hours and decreased 24 hours after exposure to anti-RLIP76 C-ter antibodies ( Figures 6D,E) .
Effects of anti RLIP76 C-ter antibodies on microvascular cells
Besides using the EAhy926 line, a model of macrovascular endothelium, we analyzed the biological effects of anti-RLIP76 C-ter antibodies on a primary microvascular cell line (HMVEC-L). When these cells were subjected to mild H 2 O 2 -induced oxidative stress, RLIP76 expression at the cell surface increased ( Figure 7A ). In H 2 O 2 -treated and in untreated HMVEC-L, anti-RLIP76 C-ter antibody-exposure for 24 hours induced 4-HNE adduct formation ( Figure 7B ), GSH depletion ( Figure 7C ) and apoptosis ( Figures 7D,E) . Both α-TCPH and the caspase inhibitor zVAD completely prevented RLIP76 C-ter antibody-induced apoptosis in HMVEC-L cells ( Figure 7F ). JNK-mediated signaling started 24 hours after cells were exposed to anti-RLIP76 C-ter antibodies ( Figure 7G ).
Discussion
In this study, using a molecular cloning strategy, we identified a new antigenic target of AECA involved in the autoimmune processes causing endothelial damage. The main finding in this study is that the C-terminal subunit of RLIP76 we cloned is a novel autoantigen in various immune-mediated diseases characterized by endothelial dysfunction, BD, SLE, SS and carotid atherosclerosis. Our findings strongly suggest that autoantibodies specific to the RLIP76 C-terminus exert pathogenetic effects on the endothelium by inducing oxidative stress-mediated apoptosis.
Our results extend current knowledge about the glutathione conjugate transporter RLIP76. We provide evidence that the C-terminal immunoreactive region of RLIP76 may be accessible to serum antibodies on the surface of both macrovascular and microvascular endothelium. Confirming published data, 23 we also found that after mild, transient oxidative stress, RLIP76 redistributes from the intracellular compartment to the plasma cell membrane. More important, we provide new evidence showing anti-RLIP76 C-ter antibodies in sera from patients with immune-mediated vascular diseases.
In our in vitro experiments, by blocking the physiological function of RLIP76 to throw out GS-HNE, these autoantibodies depleted cellular antioxidant defenses, thereby causing oxidative imbalance increasing 4-HNE intracellular levels, decreasing GSH levels and ultimately inducing apoptosis in endothelial cells under physiological conditions and after mild oxidative stress. These findings are consistent with previous studies suggesting that inhibition of RLIP76 with a rabbit specific IgG induced apoptosis. 39, 40 In our experiments, the antioxidant α-TCPH, the main component of vitamin E, counteracted the effects of anti-RLIP76 C-ter antibodies on cell apoptosis confirming that these autoantibodies induce oxidative stress-mediated apoptosis.
Oxidative stress, expressed by increased 4-HNE level, was found in several degenerative and immune-mediated diseases, confirming the idea that it could have a pathogenetic role in such diseases. [41] [42] [43] [44] [45] [46] Our findings suggest that 4-HNE could induce apoptosis also through immune-mediated mechanisms. Although the precise mechanism of 4-HNE-induced apoptosis is unclear, several studies show that 4-HNE reduces cellular GSH. 38 GSH is an endogenous thiol that plays an important role as antioxidant in regulating cellular redox status. 47 In particular, GSH has a pivotal role in protecting macromolecules, such as DNA, from cyclic adduction by 4-HNE, suppressing the oxidation of lipids and, consequently, reducing the formation of 4-HNE. Hence, depletion of GSH in tissues finally leads to an increased formation of oxidized products. 48 Decreased GSH levels have been found in numerous diseases such as cancer, viral infections and immune dysfunctions. 49 As expected, cytofluorimetric analysis showed that anti-RLIP76 C-ter antibodies activate JNK, thus inducing the signaling pathway typical of oxidative damage.
23, 39
Oxidative stress-mediated JNK activation is a critical component that decides cell fate in response to various stress stimuli. 50 Our study provides new evidence suggesting that the various diseases related to endothelial dysfunction may arise through a common pathogenetic mechanism, possibly involving anti-RLIP76 C-ter antibodies. We found anti-RLIP76 C-ter antibodies not only in the sera from patients with autoimmune vasculitis and vasculopathies, but also in the sera of a high percentage (41%) of patients with carotid atherosclerosis. The presence of pathogenetic serum autoantibodies specific to the RLIP76 C-terminus in patients with atherosclerosis supports the recently emerging role of the immune system in the development and progression of atherosclerosis. Atherosclerosis arises as a vascular wall response to endothelial injury. Endothelial cell apoptosis may be an important mechanism of vascular injury leading to the disruption of the endothelial barrier with vascular leak, extravasation of plasma proteins and exposure of the prothrombotic sub-endothelial matrix. 51, 52 Accumulating evidence suggests that endothelial cell apoptosis could play a critical role as an initial pathogenic event in atherosclerosis, SS and SLE. [53] [54] [55] [56] In this study we found that anti-RLIP76 antibodies bound RLIP76 on endothelial representative serum from a healthy subject; lanes 6, 10: control without serum. For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From
